Format

Send to

Choose Destination
Bioorg Med Chem. 2017 May 1;25(9):2593-2600. doi: 10.1016/j.bmc.2017.03.038. Epub 2017 Mar 19.

Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors.

Author information

1
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, PR China; Jiangsu Naique Biological Engineering Technology Company Limited, Zhenjiang 212415, PR China.
2
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, PR China.
3
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, PR China. Electronic address: xuchn@nju.edu.cn.
4
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, PR China; Jiangsu Naique Biological Engineering Technology Company Limited, Zhenjiang 212415, PR China. Electronic address: zhuhl@nju.edu.cn.

Abstract

Focal adhesion kinase (FAK) is an important drug target that plays a fundamental role in mediating signal transduction system. We report herein the discovery of a novel class of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton with improved potency toward FAK. All of the 17 new synthesized compounds were assayed for the anticancer activities against four cancer cells, HepG2, Hela, SW116 and BGC823. Because of the combination of 1,4-benzodioxan, 1,3,4-oxadiazole and piperazine ring, most of them exhibited remarkable antitumor activities. Notably, compound 5m showed the most potent biological activities (IC50=5.78μM for HepG2, and IC50=47.15μM for SW1116), and its anti-FAK inhibitory activity (IC50=0.78μM) was also the best. Computational docking studies also showed that compound 5m has interaction with FAK key residues in the active site.

KEYWORDS:

Antitumor activity; Benzodioxan; FAK; Oxadiazoles; Piperazine

PMID:
28363444
DOI:
10.1016/j.bmc.2017.03.038
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center